MA35342B1 - Composés de-pipéridinyle utiles comme inhibiteurs de la tankyrase - Google Patents
Composés de-pipéridinyle utiles comme inhibiteurs de la tankyraseInfo
- Publication number
- MA35342B1 MA35342B1 MA36745A MA36745A MA35342B1 MA 35342 B1 MA35342 B1 MA 35342B1 MA 36745 A MA36745 A MA 36745A MA 36745 A MA36745 A MA 36745A MA 35342 B1 MA35342 B1 MA 35342B1
- Authority
- MA
- Morocco
- Prior art keywords
- tankyrase
- inhibitors
- compounds useful
- piperidinyl compounds
- formula
- Prior art date
Links
- 102000004535 Tankyrases Human genes 0.000 title abstract 3
- 108010017601 Tankyrases Proteins 0.000 title abstract 3
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 125000003386 piperidinyl group Chemical group 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 3
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 2
- 208000035475 disorder Diseases 0.000 abstract 2
- 230000011664 signaling Effects 0.000 abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/052—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being six-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D495/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms
- C07D495/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having sulfur atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D495/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Plural Heterocyclic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161507321P | 2011-07-13 | 2011-07-13 | |
| PCT/IB2012/053613 WO2013008217A1 (en) | 2011-07-13 | 2012-07-13 | 4 - piperidinyl compounds for use as tankyrase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MA35342B1 true MA35342B1 (fr) | 2014-08-01 |
Family
ID=46604017
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA36745A MA35342B1 (fr) | 2011-07-13 | 2014-02-10 | Composés de-pipéridinyle utiles comme inhibiteurs de la tankyrase |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | USRE46942E1 (enExample) |
| EP (1) | EP2731940B1 (enExample) |
| JP (1) | JP5957077B2 (enExample) |
| KR (1) | KR20140051944A (enExample) |
| CN (1) | CN103797006B (enExample) |
| AP (1) | AP2014007400A0 (enExample) |
| AU (1) | AU2012282076A1 (enExample) |
| BR (1) | BR112014000792A2 (enExample) |
| CA (1) | CA2841932A1 (enExample) |
| CO (1) | CO6880065A2 (enExample) |
| CR (1) | CR20140071A (enExample) |
| DO (1) | DOP2014000012A (enExample) |
| EA (1) | EA201490272A1 (enExample) |
| ES (1) | ES2548513T3 (enExample) |
| IL (1) | IL230430A0 (enExample) |
| MA (1) | MA35342B1 (enExample) |
| MX (1) | MX2014000536A (enExample) |
| PH (1) | PH12014500126A1 (enExample) |
| TN (1) | TN2014000016A1 (enExample) |
| WO (1) | WO2013008217A1 (enExample) |
| ZA (1) | ZA201400374B (enExample) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2013012723A1 (en) * | 2011-07-13 | 2013-01-24 | Novartis Ag | Novel 2-piperidin-1-yl-acetamide compounds for use as tankyrase inhibitors |
| RU2696572C2 (ru) | 2012-03-07 | 2019-08-05 | Инститьют Оф Кансер Ресёрч: Ройял Кансер Хоспитал (Зе) | 3-арил-5-замещенные соединения изохинолин-1-она и их терапевтическое применение |
| TW201524952A (zh) * | 2013-03-15 | 2015-07-01 | Araxes Pharma Llc | Ｋｒａｓ ｇ１２ｃ之共價抑制劑 |
| NZ717552A (en) * | 2013-08-07 | 2021-07-30 | Merck Patent Gmbh | Piperidine urea derivatives |
| ES2666729T3 (es) | 2013-09-11 | 2018-05-07 | Institute Of Cancer Research: Royal Cancer Hospital (The) | Compuestos de isoquinolin-1-ona 3-aril-5-sustituida y su uso terapéutico |
| WO2015135461A1 (zh) * | 2014-03-10 | 2015-09-17 | 四川海思科制药有限公司 | 取代的二氢苯并呋喃-哌啶-甲酮衍生物、其制备及用途 |
| BR112016025396A2 (pt) | 2014-05-07 | 2017-08-15 | Merck Patent Gmbh | derivados de heterociclil-butanamida |
| WO2016006975A2 (en) * | 2014-07-11 | 2016-01-14 | St Pharm Co., Ltd. | Novel imidazotriazinone or imidazopyrazinone derivatives, and use thereof |
| KR101739003B1 (ko) | 2014-07-11 | 2017-05-23 | 에스티팜 주식회사 | 신규한 트리아졸로피리미디논 또는 트리아졸로피리디논 유도체, 및 이들의 용도 |
| KR20160007347A (ko) | 2014-07-11 | 2016-01-20 | 에스티팜 주식회사 | 신규한 이미다조트리아지논 또는 이미다조피라지논 유도체, 및 이들의 용도 |
| WO2016006974A2 (en) * | 2014-07-11 | 2016-01-14 | St Pharm Co., Ltd. | Novel triazolopyrimidinone or triazolopyridinone derivatives, and use thereof |
| ES2773511T3 (es) * | 2015-11-02 | 2020-07-13 | Merck Patent Gmbh | Derivados de 1,4-dicarbonil-piperidilo |
| KR101777475B1 (ko) * | 2015-12-08 | 2017-09-11 | 에스티팜 주식회사 | 신규한 디히드로피라노피리미디논 유도체 및 이들의 용도 |
| AU2016378723B2 (en) | 2015-12-22 | 2021-09-30 | SHY Therapeutics LLC | Compounds for the treatment of cancer and inflammatory disease |
| WO2017156350A1 (en) | 2016-03-09 | 2017-09-14 | K-Gen, Inc. | Methods of cancer treatment |
| AU2018288841B2 (en) | 2017-06-21 | 2022-09-29 | SHY Therapeutics LLC | Compounds that interact with the Ras superfamily for the treatment of cancers, inflammatory diseases, Rasopathies, and fibrotic disease |
| JP2022510368A (ja) | 2018-12-03 | 2022-01-26 | メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング | タンキラーゼのインヒビターとしての４－ヘテロアリールカルボニル－ｎ－（フェニルまたはヘテロアリール）ピペリジン－１－カルボキサミド |
| EP3898609A1 (en) | 2018-12-19 | 2021-10-27 | Shy Therapeutics LLC | Compounds that interact with the ras superfamily for the treatment of cancers, inflammatory diseases, rasopathies, and fibrotic disease |
| CN114787150A (zh) * | 2019-08-15 | 2022-07-22 | 黑钻治疗公司 | 炔基喹唑啉化合物 |
| WO2022146614A1 (en) * | 2020-12-03 | 2022-07-07 | Washington University | Methods of treating and preventing kidney disease |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20020022636A1 (en) | 1997-09-03 | 2002-02-21 | Jia-He Li | Oxo-substituted compounds, process of making, and compositions and methods for inhibiting parp activity |
| EP1142881A4 (en) | 1999-01-14 | 2003-05-07 | Meiji Seika Kaisha | POLY (ADP-RIBOSE) POLYMERASE INHIBITORS CONSISTING OF PYRIMIDINE DERIVATIVES |
| US6710058B2 (en) * | 2000-11-06 | 2004-03-23 | Bristol-Myers Squibb Pharma Company | Monocyclic or bicyclic carbocycles and heterocycles as factor Xa inhibitors |
| DE10056312A1 (de) | 2000-11-14 | 2002-05-16 | Bayer Ag | Substituierte Amidoalkyluracile und ihre Verwendung |
| AUPR201600A0 (en) * | 2000-12-11 | 2001-01-11 | Fujisawa Pharmaceutical Co., Ltd. | Quinazolinone derivative |
| JPWO2002094790A1 (ja) | 2001-05-23 | 2004-09-09 | 三菱ウェルファーマ株式会社 | 縮合ヘテロ環化合物およびその医薬用途 |
| EP1551812B1 (en) | 2001-12-06 | 2009-03-04 | Merck & Co., Inc. | Mitotic kinesin inhibitors |
| DE10201240A1 (de) | 2002-01-15 | 2003-07-24 | Bayer Ag | Substituierte Alkyluracile und ihre Verwendung |
| AUPS019702A0 (en) | 2002-01-29 | 2002-02-21 | Fujisawa Pharmaceutical Co., Ltd. | Condensed heterocyclic compounds |
| MXPA04008014A (es) | 2002-02-19 | 2004-11-26 | Ono Pharmaceutical Co | Compuestos derivados de piridazina fusionada y farmacos que contienen estos compuestos como ingrediente activo. |
| AUPS137402A0 (en) | 2002-03-26 | 2002-05-09 | Fujisawa Pharmaceutical Co., Ltd. | Novel tricyclic compounds |
| TWI275390B (en) | 2002-04-30 | 2007-03-11 | Wyeth Corp | Process for the preparation of 7-substituted-3- quinolinecarbonitriles |
| US7183287B2 (en) | 2003-04-03 | 2007-02-27 | Pharmacia Corporation | Substituted pyrimidinones |
| WO2004111014A1 (en) | 2003-06-06 | 2004-12-23 | Vertex Pharmaceuticals Incorporated | Pyrimidine derivatives as modulators of atp-binding cassette transporters |
| NL1026826C2 (nl) | 2003-08-13 | 2007-01-04 | Pharmacia Corp | Gesubstitueerde pyridinonen. |
| WO2005061460A1 (en) | 2003-12-08 | 2005-07-07 | Cytokinetics, Inc. | Compounds, compositions, and methods |
| GB0405101D0 (en) * | 2004-03-06 | 2004-04-07 | Astrazeneca Ab | Compounds |
| US7375102B2 (en) | 2004-06-28 | 2008-05-20 | Amgen Sf, Llc | Tetrahydroquinazolin-4(3H)-one-related and tetrahydropyrido[2,3-D]pyrimidin-4(3H)-one-related compounds, compositions and methods for their use |
| ES2380702T3 (es) * | 2004-06-30 | 2012-05-17 | Janssen Pharmaceutica Nv | Derivados de 2-alquil quinazolinona sustituidos como inhibidores de PARP |
| KR20200019263A (ko) | 2004-09-02 | 2020-02-21 | 제넨테크, 인크. | 헤지호그 신호전달에 대한 피리딜 억제제 |
| GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| EP1917250B1 (en) | 2005-06-27 | 2010-07-21 | Amgen, Inc | Anti-inflammatory aryl nitrile compounds |
| SI2021337T1 (sl) * | 2006-04-25 | 2010-05-31 | Lilly Co Eli | Inhibitorji beta hidroksisteroidne dehidrogenaze |
| US8466150B2 (en) | 2006-12-28 | 2013-06-18 | Abbott Laboratories | Inhibitors of poly(ADP-ribose)polymerase |
| BRPI0816769A2 (pt) | 2007-09-12 | 2016-11-29 | Hoffmann La Roche | combinações de compostos inibidores de fosfoinositida 3-cinase e agentes quimioterapêuticos, e métodos de uso |
| ES2439705T3 (es) | 2007-10-25 | 2014-01-24 | Genentech, Inc. | Proceso para la preparación de compuestos de tienopirimidina |
| BRPI0820504A2 (pt) | 2007-11-05 | 2015-06-16 | Novartis Ag | Métodos e composições para medir ativação de wnt e para tratar cânceres relacionados a wnt |
| KR101179753B1 (ko) | 2007-11-06 | 2012-09-04 | 제일약품주식회사 | 신규한 트리시클릭 유도체 또는 이의 약학적으로허용가능한 염, 이의 제조방법 및 이를 포함하는 약학조성물 |
| AU2008345225A1 (en) * | 2007-12-21 | 2009-07-09 | University Of Rochester | Method for altering the lifespan of eukaryotic organisms |
| US8889866B2 (en) | 2008-03-27 | 2014-11-18 | Janssen Pharmaceutica, Nv | Tetrahydrophenanthridinones and tetrahydrocyclopentaquinolinones as PARP and tubulin polymerization inhibitors |
| WO2013012723A1 (en) * | 2011-07-13 | 2013-01-24 | Novartis Ag | Novel 2-piperidin-1-yl-acetamide compounds for use as tankyrase inhibitors |
-
2012
- 2012-07-13 BR BR112014000792A patent/BR112014000792A2/pt not_active IP Right Cessation
- 2012-07-13 US US15/786,125 patent/USRE46942E1/en active Active
- 2012-07-13 AU AU2012282076A patent/AU2012282076A1/en not_active Abandoned
- 2012-07-13 JP JP2014519688A patent/JP5957077B2/ja not_active Expired - Fee Related
- 2012-07-13 US US14/154,173 patent/US9163003B2/en not_active Ceased
- 2012-07-13 PH PH1/2014/500126A patent/PH12014500126A1/en unknown
- 2012-07-13 CN CN201280043558.7A patent/CN103797006B/zh not_active Expired - Fee Related
- 2012-07-13 AP AP2014007400A patent/AP2014007400A0/xx unknown
- 2012-07-13 KR KR20147003628A patent/KR20140051944A/ko not_active Withdrawn
- 2012-07-13 EP EP12742957.9A patent/EP2731940B1/en not_active Not-in-force
- 2012-07-13 EA EA201490272A patent/EA201490272A1/ru unknown
- 2012-07-13 MX MX2014000536A patent/MX2014000536A/es not_active Application Discontinuation
- 2012-07-13 ES ES12742957.9T patent/ES2548513T3/es active Active
- 2012-07-13 CA CA 2841932 patent/CA2841932A1/en not_active Abandoned
- 2012-07-13 WO PCT/IB2012/053613 patent/WO2013008217A1/en not_active Ceased
-
2014
- 2014-01-13 IL IL230430A patent/IL230430A0/en unknown
- 2014-01-15 TN TNP2014000016A patent/TN2014000016A1/en unknown
- 2014-01-17 ZA ZA2014/00374A patent/ZA201400374B/en unknown
- 2014-01-22 DO DO2014000012A patent/DOP2014000012A/es unknown
- 2014-02-10 MA MA36745A patent/MA35342B1/fr unknown
- 2014-02-12 CR CR20140071A patent/CR20140071A/es unknown
- 2014-02-13 CO CO14031176A patent/CO6880065A2/es not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| ZA201400374B (en) | 2014-10-29 |
| US9163003B2 (en) | 2015-10-20 |
| AU2012282076A1 (en) | 2014-02-27 |
| WO2013008217A1 (en) | 2013-01-17 |
| AP2014007400A0 (en) | 2014-01-31 |
| MX2014000536A (es) | 2014-12-05 |
| DOP2014000012A (es) | 2014-07-31 |
| JP5957077B2 (ja) | 2016-07-27 |
| EA201490272A1 (ru) | 2014-05-30 |
| PH12014500126A1 (en) | 2014-02-24 |
| EP2731940A1 (en) | 2014-05-21 |
| CA2841932A1 (en) | 2013-01-17 |
| CN103797006A (zh) | 2014-05-14 |
| US20150126513A1 (en) | 2015-05-07 |
| NZ620426A (en) | 2015-08-28 |
| CN103797006B (zh) | 2016-01-27 |
| EP2731940B1 (en) | 2015-08-19 |
| KR20140051944A (ko) | 2014-05-02 |
| USRE46942E1 (en) | 2018-07-10 |
| ES2548513T3 (es) | 2015-10-19 |
| IL230430A0 (en) | 2014-03-31 |
| CO6880065A2 (es) | 2014-02-28 |
| TN2014000016A1 (en) | 2015-07-01 |
| BR112014000792A2 (pt) | 2017-10-31 |
| JP2014522855A (ja) | 2014-09-08 |
| CR20140071A (es) | 2014-10-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA35342B1 (fr) | Composés de-pipéridinyle utiles comme inhibiteurs de la tankyrase | |
| MA37762A1 (fr) | Composés n-aryltriazole utilisés comme antagonistes de lpar | |
| MA37764A1 (fr) | Composés n-alkyltriazole utilisés comme antagonistes de lpar | |
| MA38398B1 (fr) | Composés biaryle amides en tant qu'inhibiteurs de kinase | |
| WO2019035863A8 (en) | PYRUVATE KINASE ACTIVATORS FOR USE IN THE TREATMENT OF HEMATOLOGICAL DISORDERS | |
| MA35184B1 (fr) | Antagonistes de trpv4 | |
| MA41562A1 (fr) | Agonistes d'apj 4-hydroxy-3-(heteroaryl)pyridine-2-one a utiliser dans le traitement de troubles cardio-vasculaires | |
| MA53399B1 (fr) | Pyrazoles substitués en tant qu`inhibiteurs de la kallicréine plasmatique humaine | |
| MA39211A1 (fr) | Composés tricycliques comme agents anti-cancers | |
| MA38661A1 (fr) | Composés hétéro-aromatiques et leur utilisation en tant que ligands d1 de la dopamine | |
| MA39995B1 (fr) | Composés destinés à traiter l'amyotrophie spinale | |
| MA40111A1 (fr) | Dérivés du tétrahydronaphtalène inhibant la protéine mcl-1 | |
| MA34837B1 (fr) | Composés indoliques ou analogues de ceux-ci utiles dans le traitement de la dégénérescence maculaire liée à l'âge (dmla) | |
| MA37959A2 (fr) | Dérivés de 5-phénoxy-3h-pyrimidin-4-one et leur utilisation en tant qu'inhibiteurs de la transcriptase inverse du vih | |
| MA40225A (fr) | Composés dihydroisoquinolinone substitués | |
| MA37886A1 (fr) | Nouvelles pyridinones bicycliques | |
| MA34896B1 (fr) | Inhibiteurs du virus de l'hepatite c | |
| MA39165A1 (fr) | Dérivés de benzimidazole-proline pour leurs utilisations dans le traitement du syndrome des etats crepusculaires | |
| MA38810B1 (fr) | Inhibiteurs de rorc2 méthodes d'utilisation associées | |
| MA43409B1 (fr) | Composés polycycliques à utiliser en tant qu'inhibiteurs de la tyrosine kinase de bruton | |
| MA37765A1 (fr) | Composés de pyrazole substitués utilisés comme antagonistes de lpar | |
| MA39152A1 (fr) | Cyclopentanes substitués en 1,2 utilisés comme antagonistes du récepteur d'orexine | |
| MA37439A1 (fr) | Inhibiteurs de dgat1 à ponts éthers cycliques pour le traitement de troubles medies par l'acyle coa-diacylglycerol transferase 1 (dgat1). | |
| MA38410A1 (fr) | Composés d'azétidinyloxyphénylpyrrolidine | |
| MA32061B1 (fr) | Triazolopyridazines en tant qu'inhibiteurs de par1, production de celles-ci, et utilisation en tant que médicaments |